Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate-binding protein 6 (GBP6)
- Target
- GBP6
- Molecular classification
- Enzyme (specifically, GTPase), Interferon-inducible protein, Member of the dynamin superfamily of large GTPases[1][3]
01
Overview
Guanylate-binding protein 6 (GBP6) is a large, interferon-induced GTPase that belongs to the dynamin superfamily and is encoded by the GBP6 gene in humans. GBP6 is characterized by its ability to hydrolyze GTP to both GDP and GMP, and it is highly responsive to interferon stimulation. As part of the guanylate-binding protein family, it serves as a multifaceted regulator in innate and adaptive immune responses and is implicated in defense against a wide variety of pathogens. GBP6 is integral to interferon-regulated responses and is involved in inflammatory signaling, vascular inflammation, and tumorigenesis. Recent evidence highlights its potential roles as a diagnostic and prognostic biomarker in cancers such as oral squamous cell carcinoma, and as a modulator of immune response during infection and atherogenesis. Despite its functional importance in immunity, GBP6 currently is not a direct therapeutic target for any approved drug[1][2][3].
- Other names
- Guanylate binding protein family member 6GBP6GBP-6DKFZp686G0786GTP-binding protein 6Guanine nucleotide-binding protein 6
02
Mechanism of action
Not applicable; no approved drugs target GBP6 directly. GBP6 mediates effects via interferon signaling and GTP hydrolysis.
03
Biological functions
Immune response (induced by interferons, key regulator in innate immunity)GTP hydrolysis (converts GTP to GDP and GMP)Inflammatory signaling modulationRegulation of immune cell activationCell-autonomous immunity against pathogens (particularly bacterial, viral, and protozoan)[1][2][3]
04
Disease associations
Cancer (notably, oral squamous cell carcinoma, non-small cell lung cancer; prognostic biomarker roles)Inflammation (associated with vascular inflammation and atherogenesis)Infection (as an innate immunity mediator)Other: Placental immune modulation; potential role in adaptive immune function variability in different species[2]
05
Safety considerations
No specific safety concerns or therapeutic challenges reported for targeting GBP6. General safety concerns may arise due to its broad role in immune regulation.
06
Interacting drugs
No known direct-interacting drugs identified in current literature or curated resources as of September 2025[2].
07
Biomarkers
Prognostic biomarker in oral squamous cell carcinoma (low GBP6 expression correlates with poor prognosis)Differential expression signature in non-small cell lung cancer and inflammatory conditions[2]
Beyond the preview
Go deeper on Guanylate-binding protein 6 (GBP6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guanylate-binding protein 6 (GBP6).